An Introduction to Immunotherapy
Cancer immunotherapy has brought significant improvements for patients in terms of survival and quality of life. Monoclonal antibodies and immune checkpoint inhibitors are now an established part of the treatment paradigm for many types of cancer, but challenges remain around its efficacy, targeting and toxicity.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Emerging data with immunotherapy in esophageal squamous cell carcinoma and potential impact for clinical practice
Join Dr Elizabeth Smyth as she highlights the latest clinical data on the use of immunotherapy in the management of esophageal squamous cell carcinoma (ESCC).
- Describe the efficacy data for emerging treatments, including first- and second-line immunotherapy, for ESCC
- Recall the safety data for emerging treatments for ESCC
- Discuss how the latest data for emerging treatments for ESCC could impact clinical practice
Robin Foà: Sustainability and Accessibility of CAR-T Cell Therapy
We are delighted to speak with Dr Robin Foà, one of our Editorial Board members for touchREVIEWS in Oncology & Haematology, to discuss the sustainability and accessibility of CAR-T Cell Therapy as well as the challenges associated with this treatment. Questions Could you give us a brief overview of the current approval status of CAR-T […]
Michael Atkins: Safe and Effective Use of Immune Checkpoint Inhibitors in Patients with Cancer
Dr Michael Atkins (MedStar Georgetown University Hospital, Washington, DC, USA) shares three areas for development to help improve the safe and effective use of immune checkpoint inhibitors. 1. Having a rational approach to stopping therapy (00:50-02:20) 2. An improved understanding of toxicity and response (02:20-04:25) 3. The role of combining and sequencing immunotherapy with standard […]
Lyudmila A Bazhenova, WCLC 2021: Challenges of Widespread Immunotherapy
touchONCOLOGY joins Prof Lyudmila A Bazhenova (University of California San Diego, CA) at WCLC 2021 to discuss the challenges faced when expanding patients receiving immunotherapy for the treatment of non-small cell lung cancer. Questions 1. What has been the impact of immunotherapy in the treatment of non-small cell lung cancer (NSCLC)? (00:12-00:51) 2. What are […]
New Checkpoint Inhibitors and Immunotherapies for Solid Tumours
touchREVIEWS in Oncology & Haematology. 2021;17(2):90–4 DOI: https://doi.org/10.17925/OHR.2021.17.2.90
The antitumor activity of immune checkpoint inhibotors in various solid and haematologic malignancies has substantially increased immunotherapy implications for cancer. Once only a niche treatment for selected cancers (renal cancer and melanoma), now cancer immunotherapy has become an important option for many patients, even moving into the first-line systemic treatment setting for melanoma, non-small cell […]
Rahul Aggarwal, ESMO 2021: Ceralasertib in ARID1A-deficient and ARID1A-intact Advanced Solid Tumour Malignancies
touchONCOLOGY joins Prof Rahul Aggarwal (UCSF School of Medicine, San Francisco, CA, USA), to discuss the interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumour malignancies. Questions 1. Could you tell us a little about ARID1A alterations in solid tumours and potential therapeutic targets in […]
David S Hong, ESMO 2021: Gavocabtagene Autoleucel Dose Escalation in Refractory Mesothelin-expressing Solid Tumors (PART TWO)
touchONCOLOGY joins Professor David S Hong (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) at ESMO 2021 to discuss the safety and activity of gavocabtagene autoleucel in a dose-escalation study in patients with refractory ovarian cancer, malignant mesothelioma, cholangiocarcinoma or non-small cell lung cancer. To view Part One, click here. Questions […]
David S Hong, ESMO 2021: Gavocabtagene Autoleucel Dose Escalation in Refractory Mesothelin-expressing Solid Tumors (PART ONE)
touchONCOLOGY joins Professor David S Hong (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) at ESMO 2021 to discuss the safety and activity of gavocabtagene autoleucel in a dose-escalation study in patients with refractory ovarian cancer, malignant mesothelioma, cholangiocarcinoma or non-small cell lung cancer. To view Part Two, click here. Questions 1. […]
Omid Hamid, ASCO 2021: Nemvaleukin Alfa and the ARTISTRY-2 Trial
touchONCOLOGY joins Dr Omid Hamid (Chief, Translational Research and Immunotherapy, Director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, Los Angeles, CA, USA) at ASCO 2021 to discuss nemvaleukin alfa and the ARTISTRY-2 trial. The abstract ‘Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2’ (NCT03861793) (abstract number 2552) was presented […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!